Darifenacin

🧮 Dose calculator

Overactive bladder · Regimen source: FDA Darifenacin ER · 2

• • Swallow whole. Moderate hepatic impairment or potent CYP3A4 inhibitors: max 7.5 mg; severe hepatic impairment not recommended. FDA Darifenacin ER · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Darifenacin ER · 8.1

  “Risk Summary There are no available data on darifenacin use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Darifenacin ER · 8.2

  “Risk Summary There are no data on the presence of darifenacin in human milk, the effects on the breastfed infant, or the effects of darifenacin on milk production.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Darifenacin ER · 8.4

  “The safety and effectiveness of darifenacin extended-release tablets in pediatric patients have not been established.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Darifenacin ER · 8.5

  “No dose adjustment is recommended for elderly patients [see Clinical Pharmacology ( 12.3 ) and Clinical Studies ( 14 )] .”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.